Visudyne
(Verteporfin)ApprovedSmall molecule
Verteporfin is used to treat a type of age-related macular degeneration (a disease that causes vision loss in older people) by being injected into the bloodstream and then activated by a laser to destroy abnormal blood vessels in the eye.[2] Visudyne is currently approved and in use across 25 indications[4].[1]
Visudyne is one of 502 small molecule programs targeting Nevoid Basal Cell Carcinoma Syndrome. It is currently in Approved.
25
Indications
27
Total Trials
8
Active Trials
501
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 25 indications
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Visudyne
BBausch Health Americas, Inc.
Approved
Adriamycin
GGynecologic Oncology Group
Preclinical
Megace
Bristol-Myers SquibbPreclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Methylthioninium Chloride
PProvepharm SAS
Preclinical
Nubain
AAultman Health Foundation
Preclinical
Cortef
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Chirocaine
PPurdue Pharma LP
Preclinical
Vfend
PPrism Pharmaceuticals
Preclinical
Apatinib Mesylate
BBukwang Pharmaceutical
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Retinopathy3 trials
AMD2 trials
Pancreatic Cancer2 trials
17 more indications
Prostate Cancer1 trial
Neovascular AMD1 trial
Safety and Efficacy1 trial
Optical Coherence Tomography1 trial
Polypoidal choroidal vasculopathy1 trial
ESS1 trial
Dexamethasone1 trial
Malignancies1 trial
Photo-induction as a Means to Improve Cisplatin Delivery to Pleural Malignancies
Terminated·—·Phase 1·NCT02702700·1 enrolled
Airway obstruction1 trial
Unspecified1 trial
Lucentis KAV Study
Completed·TThe Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery·Phase 3·NCT01570608·51 enrolled
Regulatory
FDA Approval Timeline[5]
Apr 12, 2000
VISUDYNE
NDA NDA021119
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Visudyne drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Verteporfin. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company
- BBausch Health Americas, Inc.